
    
      In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose
      of 2500 mg/m2 BID on each day of study.

      Subjects will be evaluated in 3 Cohorts:

      Cohort 1: Molecular High Risk Medulloblastoma Cohort 2: Molecular Very High Risk
      Medulloblastoma Cohort 3: Relapsed/Refractory Medulloblastoma

      A total of 118 subjects across all cohorts will be enrolled to ensure that there will be 107
      evaluable subjects (32-39 per cohort)
    
  